Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
- NCT ID
| Study title | Condition | Phase | Location | NCT ID |
|---|---|---|---|---|
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis |
Diffuse Cutaneous Systemic Sclerosis | Phase2 | Argentina Austria Belgium Brazil China Colombia France Germany Greece Hungary India Italy Japan Malaysia Mexico Poland Portugal South Korea Spain Taiwan Thailand Turkey (Türkiye) United Kingdom United States Vietnam View all |
NCT06470048 |
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy |
Primary IgA Nephropathy | Phase3 | Argentina Australia Belgium Brazil China Colombia Czechia Denmark France Germany Hong Kong Hungary India Israel Italy Japan Malaysia Mexico Netherlands Singapore Slovenia South Korea Spain Sweden Taiwan Thailand Turkey (Türkiye) United Kingdom United States View all |
NCT04557462 |
Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI) |
Acute Kidney Injury Due to Sepsis | Phase2 | Argentina Australia Austria Belgium Brazil Canada China France Germany Hungary India Italy Japan South Africa Spain Thailand United Kingdom United States View all |
NCT05996835 |
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V |
Lupus Nephritis | Phase2 | Argentina Brazil China Colombia France Germany Hong Kong Hungary India Israel Malaysia Mexico Philippines Portugal Puerto Rico Singapore Spain Turkey (Türkiye) United Kingdom United States View all |
NCT05268289 |
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). |
Systemic Lupus Erythematosus | Phase3 | Argentina Australia Brazil Bulgaria Canada Chile China Colombia Czechia France Germany Guatemala Hungary India Israel Italy Japan Malaysia Mexico Poland Portugal Romania South Africa South Korea Spain Taiwan Thailand United States View all |
NCT06133972 |
Asciminib Roll-over Study |
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase4 | Argentina Austria Brazil Bulgaria Canada China Czechia France Germany Italy Malaysia Mexico Oman Poland Portugal Romania Russia South Korea Spain Turkey (Türkiye) United Kingdom United States Vietnam View all |
NCT04877522 |
Iptacopan in Patients With ANCA Associated Vasculitis |
Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis | Phase2 | Argentina Australia Austria Belgium Canada China Czechia Denmark France Germany Hungary Netherlands Spain Turkey (Türkiye) United Kingdom United States View all |
NCT06388941 |
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia |
Warm Autoimmune Hemolytic Anemia (wAIHA) | Phase3 | Argentina Australia China Germany Italy United Kingdom United States View all |
NCT05648968 |
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) |
Polymyalgia Rheumatica | Phase3 | Argentina Australia Belgium Brazil Colombia Czechia Denmark France Germany Hungary Israel Italy Japan Mexico Netherlands Poland South Africa Spain United Kingdom United States View all |
NCT06331312 |
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) |
Relapsing Multiple Sclerosis | Phase3 | Argentina Brazil Bulgaria Canada China Croatia Czechia Estonia France Germany Greece India Italy Japan Mexico Poland Portugal Puerto Rico Romania Slovakia Slovenia South Africa Spain Sweden Turkey (Türkiye) United Kingdom United States View all |
NCT05156281 |